ImmunityBio

IBRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.097 B

$7.64 +4.37%

Close of 7 Aug 2026

Revenue

$113.3M

#2475 by revenue

Earnings

-$351.5M

Loss-making

Shares outstanding

1,059,836,273

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#17VaxcytePCVX$8.64B
#18ImmunovantIMVT$8.25B
#19ImmunityBioIBRX$8.10B
#20Twist BioscienceTWST$7.25B
#21CG OncologyCGON$6.62B

Where these numbers come from

Share counts and financials for ImmunityBio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.